J Prev Med Public Health.
2009 Nov;42(6):371-376. 10.3961/jpmph.2009.42.6.371.
Risk Assessment and Pharmacogenetics in Molecular and Genomic Epidemiology
- Affiliations
-
- 1Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.
- 2Cancer Research Institute and Institute of Health Policy and Management, Seoul National University, Seoul, Korea.
- 3Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Korea. jychoi@inje.ac.kr
- KMID: 1105309
- DOI: http://doi.org/10.3961/jpmph.2009.42.6.371
Abstract
- In this article, we reviewed the literature on risk assessment (RA) models with and without molecular genomic markers and the current utility of the markers in the pharmacogenetic field. Epidemiological risk assessment is applied using statistical models and equations established from current scientific knowledge of risk and disease. Several papers have reported that traditional RA tools have significant limitations in decision-making in management strategies for individuals as predictions of diseases and disease progression are inaccurate. Recently, the model added information on the genetic susceptibility factors that are expected to be most responsible for differences in individual risk. On the continuum of health care, from diagnosis to treatment, pharmacogenetics has been developed based on the accumulated knowledge of human genomic variation involving drug distribution and metabolism and the target of action, which has the potential to facilitate personalized medicine that can avoid therapeutic failure and serious side effects. There are many challenges for the applicability of genomic information in a clinical setting. Current uses of genetic markers for managing drug therapy and issues in the development of a valid biomarker in pharmacogenetics are discussed.
